Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: SARS COV2 Clear all
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study of Ad26.COV2.S in Adults (COVID-19)

NCT04436276
View directory record Official record
Conditions
Covid-19 Prevention
Interventions
Ad26.COV2.S, Placebo
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years and older
Enrollment
1,085 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
7
States / cities
San Diego, California • Melbourne, Florida • Peoria, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Jul 22, 2026, 5:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Relative Bioavailability Study of Nirmatrelvir/Ritonavir 4 Different Fixed Dose Combination Tablets Relative to the Commercial Tablets in Healthy Participants

NCT05525910
View directory record Official record
Conditions
Biological Availability, Healthy Participants
Interventions
Nirmatrelvir/ ritonavir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jul 22, 2026, 5:57 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Study of S-892216 Long-acting Injectable (LAI) in Healthy Adult Participants

NCT07093580
View directory record Official record
Conditions
Healthy Participants
Interventions
S-892216-LAI, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
2
States / cities
Lenexa, Kansas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Jul 22, 2026, 5:57 PM EDT
Completed No phase listed Observational

ScreenNC, a Study to Determine the Number of Asymptomatic Individuals Who Have Antibodies to the Virus That Causes COVID-19

NCT04367740
View directory record Official record
Conditions
Asymptomatic Condition, Infection Viral, Coronavirus Infections, Severe Acute Respiratory Syndrome Coronavirus 2, Coronaviridae Infections, RNA Virus Infections, Virus Diseases, Communicable Disease
Interventions
To assess for development of IgG antibodies against SARS-CoV2
Diagnostic Test
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 99 Years
Enrollment
6,313 participants
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 8, 2023 · Synced Jul 22, 2026, 5:57 PM EDT
Active, not recruiting Phase 2 Interventional

The Long COVID Treatment Trial

NCT07128082
View directory record Official record
Conditions
Long COVID
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Scripps Translational Science Institute
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Jul 22, 2026, 5:57 PM EDT
Active, not recruiting Not applicable Interventional

RADx-UP Phase 3D (Oregon Saludable: Juntos Podemos)

NCT05910879
View directory record Official record
Conditions
Health Behavior, Health Care Utilization, Vaccine Hesitancy
Interventions
Self-Affirmation Implementation Intentions (SAII) Intervention, Promotores de Salud (Health Education)
Behavioral
Lead sponsor
University of Oregon
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Jul 22, 2026, 5:57 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of USB002 for Respiratory Distress Due to COVID-19

NCT04778059
View directory record Official record
Conditions
2019 Novel Coronavirus Infection, COVID-19 Virus Infection, SARS Coronavirus 2 Infection, SARS-CoV-2 Infection, Respiratory Distress Syndrome, Adult, Adult Respiratory Distress Syndrome
Interventions
USB002, Placebo
Drug
Lead sponsor
US Biotest, Inc.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Jul 22, 2026, 5:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Culturally-Targeted COVID-19 Communication and SARS-CoV-2 Antibody Testing Evaluation and Uptake

NCT04957082
View directory record Official record
Conditions
SARS-CoV2 Infection
Interventions
Culturally Targeted SARS-CoV-2 Communication, General SARS-CoV-2 Communication
Behavioral
Lead sponsor
Michigan State University
Other
Eligibility
18 Years and older
Enrollment
666 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Flint, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 27, 2024 · Synced Jul 22, 2026, 5:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Motivation, Syringe Exchange, and COVID-19

NCT05534061
View directory record Official record
Conditions
COVID-19 Pandemic
Interventions
Connect2Test
Behavioral
Lead sponsor
University of Oregon
Other
Eligibility
18 Years and older
Enrollment
349 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 27, 2024 · Synced Jul 22, 2026, 5:57 PM EDT
Terminated Not applicable Interventional Results available

Diagnostic Performance of an Antigen Test for SARS-CoV-2 Infection (COVID-19)

NCT04610489
View directory record Official record
Conditions
Covid-19
Interventions
Quidel Sofia SARS Antigen FIA
Diagnostic Test
Lead sponsor
Carilion Clinic
Other
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 16, 2021 · Synced Jul 22, 2026, 5:57 PM EDT
Completed No phase listed Observational

Immunogenicity and Safety of Commercially Available Vaccines Against SARS-CoV-2 (COVID-19) in Patients With Hematologic Malignancies

NCT04748185
View directory record Official record
Conditions
Monoclonal B-Cell Lymphocytosis, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, B-cell Non Hodgkin Lymphoma, Hodgkin Lymphoma
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 9, 2023 · Synced Jul 22, 2026, 5:57 PM EDT
Completed No phase listed Observational

A Multicenter Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab

NCT04847596
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Ofatumumab, Covid-19 vaccine
Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
Phoenix, Arizona • Owosso, Michigan • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2023 · Synced Jul 22, 2026, 5:57 PM EDT
Completed No phase listed Observational

Asymptomatic SARS-CoV-2 Detection in Children

NCT04853316
View directory record Official record
Conditions
Covid19, SARS-CoV-2
Interventions
Not listed
Lead sponsor
University of Calgary
Other
Eligibility
Up to 18 Years
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
Birmingham, Alabama • San Diego, California • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Jul 22, 2026, 5:57 PM EDT
Completed Phase 2 Interventional Results available

SAFEty Study of Early Infusion of Vitamin C for Treatment of Novel Coronavirus Acute Lung Injury (SAFE EVICT CORONA-ALI)

NCT04344184
View directory record Official record
Conditions
COVID-19, Lung Injury, Acute, Kidney Injury
Interventions
L-ascorbic acid, Placebo
Drug · Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Jul 22, 2026, 5:57 PM EDT
Withdrawn Phase 2 Interventional

COVID-19 ThromboprophylaXIs Study of Novel FXIa Inhibitor Frunexian (EP-7041) in ICU Patients

NCT05040776
View directory record Official record
Conditions
Thrombopenia, Covid19
Interventions
EP-7041 Injection
Drug
Lead sponsor
eXIthera Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Jul 22, 2026, 5:57 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19

NCT04412668
View directory record Official record
Conditions
SARS-CoV-2 (COVID-19) Severe Pneumonia
Interventions
Efzofitimod 1 mg/kg, Efzofitimod 3 mg/kg, Placebo
Drug
Lead sponsor
aTyr Pharma, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
8
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2023 · Synced Jul 22, 2026, 5:57 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Safety and Immunogenicity of mRNA-1273 Vaccine to Prevent COVID-19 in Adult Organ Transplant Recipients and in Healthy Adult Participants

NCT04860297
View directory record Official record
Conditions
SARS-CoV-2
Interventions
mRNA-1273
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
15
States / cities
Mesa, Arizona • San Diego, California • New Haven, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2024 · Synced Jul 22, 2026, 5:57 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults

NCT07536308
View directory record Official record
Conditions
COVID-19
Interventions
OCU500
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
6
States / cities
Decatur, Georgia • Baltimore, Maryland • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 22, 2026, 5:57 PM EDT
Completed Phase 2Phase 3 Interventional

A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.

NCT05975060
View directory record Official record
Conditions
COVID-19
Interventions
XBB.1.5 Vaccine (Booster), XBB.1.5 Vaccine (single dose)
Biological
Lead sponsor
Novavax
Industry
Eligibility
18 Years to 54 Years
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
30
States / cities
Mobile, Alabama • Sacramento, California • Colorado Springs, Colorado + 26 more
Source: ClinicalTrials.gov public record
Updated May 29, 2024 · Synced Jul 22, 2026, 5:57 PM EDT
Completed Not applicable Interventional Results available

Dulce Digital-COVID Aware (DD-CA) Discharge Texting Platform for US/Mexico Border Hispanics With Diabetes + COVID-19

NCT04591015
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Covid19
Interventions
Hospital: DD-CA, Hospital: Usual Care (UC)
Behavioral
Lead sponsor
Scripps Whittier Diabetes Institute
Other
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Jul 22, 2026, 5:57 PM EDT
Completed Phase 2 Interventional Results available

A Trial of Aclaris Therapeutics, Inc. (ATI)-450 in Patients With Moderate-severe Novel Coronavirus Disease 2019 (COVID-19)

NCT04481685
View directory record Official record
Conditions
Covid19
Interventions
ATI-450, Placebo
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Jul 22, 2026, 5:57 PM EDT
Terminated Phase 2 Interventional Results available

Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19

NCT04347226
View directory record Official record
Conditions
Solid Tumor, Sars-CoV2, Hematological Malignancy
Interventions
BMS-986253
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Jul 22, 2026, 5:57 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

High-Dose Moderna mRNA-1273 Booster Study for Lung Transplant Recipients

NCT05280158
View directory record Official record
Conditions
Lung Transplant Recipient, SARS-CoV-2, Immunosuppression
Interventions
mRNA-1273 (Moderna COVID-19 vaccine)
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Jul 22, 2026, 5:57 PM EDT
Completed Phase 1 Interventional

Clinical Trial to Evaluate the Safety of RQ-01 in SARS-CoV-2 Positive Subjects

NCT06063330
View directory record Official record
Conditions
COVID-19, Infectious Disease, Symptomatic COVID-19 Infection Laboratory-Confirmed, SARS CoV 2 Infection
Interventions
RQ-001, Placebo
Combination Product · Other
Lead sponsor
Red Queen Therapeutics, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
6
States / cities
Los Angeles, California • Miami, Florida • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2024 · Synced Jul 22, 2026, 5:57 PM EDT